BEERSE, Belgium, May 23, 2014 /PRNewswire/ --
- Research in haematological malignancies features VELCADE(R), siltuximab,
ibrutinib and daratumumab
- Note: This release corresponds to EHA abstracts S1345, P958, P957, P369, P353,
P960, P1211, P1209, P461, P356, P350, P434, P109
Janssen Pharmaceutica NV announced data related to four compounds have been selected for presentation at the 19th European Hematology Association Congress (EHA) being held June 12-15, 2014 in Milan, Italy.
Data include VELCADE(R) (bortezomib), a first-in-class proteasome inhibitor to treat patients with multiple myeloma, which has also been investigated as a treatment for newly diagnosed patients with mantle cell lymphoma (MCL); siltuximab, an anti-interleukin-6 (IL-6) chimeric monoclonal antibody which recently received a positive CHMP opinion for the treatment of multicentric Castleman's disease (MCD). Data will also be presented for ibrutinib, an investigational compound which targets and blocks a specific protein (Bruton's tyrosine kinase) inhibiting cancer cell survival, in relapsed/refractory chronic lymphocytic leukaemia (CLL), MCL and other B-cell malignancies, and daratumumab, an investigational human CD38 monoclonal antibody being studied in multiple myeloma and other B-cell malignancies.
"Janssen has had a momentous year in haematology and has made significant progress across our portfolio since last year's EHA meeting. We are looking forward to presentations this year, which highlight important clinical data across our haematology compounds," said Jane Griffiths, Company Group Chairman of Janssen Europe, the Middle East and Africa (EMEA). "At Janssen, we are committed to pursuing compelling science, where the need, and opportunity for impact, are greatest for patients."
List of Company-Sponsored Research to Be Presented
VELCADE
The following VELCADE data have been accepted for presentation at EHA and were sponsored by Janssen or jointly sponsored by Janssen and its collaboration partner Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited:
- Phase 3 study of frontline rituximab, cyclophosphamide, doxorubicin, and
prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in
transplantation-unsuitable mantle cell lymphoma (MCL) patients (Abstract S1345) Oral
abstract session: Aggressive Non-Hodgkin lymphoma - Clinical. Sunday 15 June 2014,
10:30-10:45 CEST in Auditorium (NW - Level 3) Lead Author: Tadeusz Robak, M.D., PhD,
Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital,
Lodz, Poland
- Subcutaneous (SC) versus intravenous (IV) bortezomib in patients with relapsed
multiple myeloma (MM): subanalysis of patients with renal impairment in the phase 3
MMY-3021 study. (Abstract P958) Poster presentation session: Myeloma and other
monoclonal gammopathies - Clinical 3 (Poster). Saturday 14 June 2014, 17:45-19:00 CEST
in e-Poster Area (NW - Level 0) Lead Author: Philippe Moreau, M.D., University
Hospital, Nantes, France
- First-line therapy for multiple myeloma (MM): results from the second interim
analysis of the real-world, international, non-interventional EMMOS study. (Abstract
P957) Poster presentation session: Myeloma and other monoclonal gammopathies -
Clinical 3 (Poster). Saturday 14 June 2014, 17:45-19:00 CEST in e-Poster Area (NW -
Level 0) Lead Author: Mohamad Mohty, M.D., PhD, Saint-Antoine Hospital, Pierre & Marie
Curie University, Paris, France
- Randomized phase 2 study of bortezomib, thalidomide, and dexamethasone with or
without cyclophosphamide as induction therapy in previously untreated multiple myeloma
(MM): Long-term follow-up results. (Abstract P369) Poster presentation session:
Myeloma and other monoclonal gammopathies - Clinical 2 (Poster). Friday 13 June 2014,
17:45-19:00 CEST in Poster Area (NW - Level 0) Lead Author: Heinz Ludwig, M.D.,
Wilhelminen Cancer Research Institute, c/o First Department of Medicine, Center for
Oncology, Haematology and Palliative Care, Wilhelminenspital, Vienna
- Preliminary pre-randomization results from a phase 3 study of frontline
subcutaneous (SC) bortezomib-based induction and consolidation in
transplantation-eligible multiple myeloma (MM) patients (PTS). (Abstract P353) Poster
presentation session: Myeloma and other monoclonal gammopathies - Clinical 1 (Poster).
Friday 13 June 2014, 17:45-19:00 CEST in Poster Area (NW - Level 0) Lead Author: Noemi
Horvath, M.D., Division of Haematology, SA Pathology/Royal Adelaide Hospital,
Adelaide, SA
- Effects of single-agent bortezomib (BTZ) as post-transplant consolidation on
multiple myeloma (MM)-related bone disease: First results from a multicenter,
randomized phase 2 study. (AbstractP960) Poster presentation session: Myeloma and
other monoclonal gammopathies - Clinical 3 (Poster). Saturday 14 June 2014,
17:45-19:00 CEST in e-Poster Area (NW - Level 0) Lead Author: Orhan Sezer, M.D., PhD.,
Department of Hematology and Stem Cell Transplantation, Memorial Hospital, Istanbul
Siltuximab
Two Janssen-sponsored abstracts for siltuximab have been accepted for presentation at EHA:
- Inflammatory and anemia-related markers in a phase 2, randomized,
double-blind, placebo controlled study of siltuximab (ANTI-IL 6 monoclonal antibody)
in multicentric Castleman's disease patients. (Abstract P1211) Poster presentation
session: Non-malignant hematologic disorders (Poster). Saturday 14 June 2014,
17:45-19:00 CEST in Poster Area (NW - Level 0) Lead Author: Corey Casper, M.D., MPH,
Fred Hutchinson Cancer Research Center, Seattle, WA
- Improvements in hemoglobin levels and fatigue in a randomized, double blinded,
placebo controlled study (MCD3282001) of siltuximab in patients with multicentric
Castleman's Disease (MCD). (Abstract P1209) Poster presentation session: Non-malignant
hematologic disorders (Poster). Saturday 14 June 2014, 17:45-19:00 CEST in Poster Area
(NW - Level 0) Lead Author: Frits van Rhee, M.D., Ph.D., Myeloma Institute for
Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR,
United States
Ibrutinib
Ibrutinib data will be featured in more than two studies selected for presentation, and sponsored by either Janssen or its collaboration partner, Pharmacyclics, Inc.:
(CONTINUA)
